169 related articles for article (PubMed ID: 38025989)
1. Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn's Disease Initiating Biologics With 3 Years of Follow-Up.
Zhao R; Ding Z; Gupta P; Gozalo L; Bruette R; Johnson VM; Maughn K; Liu Y; Kachroo S
J Health Econ Outcomes Res; 2023; 10(2):111-120. PubMed ID: 38025989
[No Abstract] [Full Text] [Related]
2. Persistence, Dosing, and Other Treatment Patterns Among Crohn's Disease Patients Initiating Biologics in United States.
Teeple A; Sah J; Mallampati R; Adams C; Waters D; Muser E
Crohns Colitis 360; 2021 Oct; 3(4):otab076. PubMed ID: 36777272
[TBL] [Abstract][Full Text] [Related]
3. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
Louis E; Litkiewicz M; Agboton C; Armuzzi A
United European Gastroenterol J; 2024 Jun; 12(5):574-584. PubMed ID: 38717013
[TBL] [Abstract][Full Text] [Related]
5. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases.
Sah J; Teeple A; Muser E; Gutierrez C; Dassopoulos T
Curr Med Res Opin; 2022 Jul; 38(7):1093-1101. PubMed ID: 35475385
[TBL] [Abstract][Full Text] [Related]
6. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab is associated with superior treatment persistence but not with higher remission rates
Bacsur P; Matuz M; Resál T; Miheller P; Szamosi T; Schäfer E; Sarlós P; Iliás Á; Szántó K; Rutka M; Bálint A; Milassin Á; Fábián A; Bor R; Szepes Z; Molnár T; Farkas K
Therap Adv Gastroenterol; 2022; 15():17562848221144349. PubMed ID: 36600684
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
Yokoyama K; Yamazaki K; Katafuchi M; Ferchichi S
Adv Ther; 2016 Nov; 33(11):1947-1963. PubMed ID: 27664107
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn's disease.
Newman KL; Johnson LA; Stidham RW; Higgins PDR
Therap Adv Gastroenterol; 2023; 16():17562848221148254. PubMed ID: 36895282
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
Yanai H; Kagramanova A; Knyazev O; Sabino J; Haenen S; Mantzaris GJ; Mountaki K; Armuzzi A; Pugliese D; Furfaro F; Fiorino G; Drobne D; Kurent T; Yassin S; Maharshak N; Castiglione F; de Sire R; Nardone OM; Farkas K; Molnar T; Krznaric Z; Brinar M; Chashkova E; Livne Margolin M; Kopylov U; Bezzio C; Bar-Gil Shitrit A; Lukas M; Chaparro M; Truyens M; Nancey S; Lobaton T; Gisbert JP; Saibeni S; Bacsúr P; Bossuyt P; Schulberg J; Hoentjen F; Viganò C; Palermo A; Torres J; Revés J; Karmiris K; Velegraki M; Savarino E; Markopoulos P; Tsironi E; Ellul P; Calviño Suárez C; Weisshof R; Ben-Hur D; Naftali T; Eriksson C; Koutroubakis IE; Foteinogiannopoulou K; Limdi JK; Liu E; Surís G; Calabrese E; Zorzi F; Filip R; Ribaldone DG; Snir Y; Goren I; Banai-Eran H; Broytman Y; Amir Barak H; Avni-Biron I; Ollech JE; Dotan I; Aharoni Golan M
J Crohns Colitis; 2022 Dec; 16(12):1882-1892. PubMed ID: 35895074
[TBL] [Abstract][Full Text] [Related]
12. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of biologics for Crohn's disease in adults: lessons learned from real-world studies.
Tursi A; Mocci G; Del Gaudio A; Papa A
Expert Opin Biol Ther; 2024 Mar; 24(3):171-189. PubMed ID: 38321868
[TBL] [Abstract][Full Text] [Related]
14. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
Olivera P; Thiriet L; Luc A; Baumann C; Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2017 Jun; 23(6):976-985. PubMed ID: 28333755
[TBL] [Abstract][Full Text] [Related]
15. Dose escalation of biologics in Crohn's disease: critical review of observational studies.
Einarson TR; Bereza BG; Ying Lee X; Lelli F
Curr Med Res Opin; 2017 Aug; 33(8):1433-1449. PubMed ID: 28537467
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
Welty M; Mesana L; Padhiar A; Naessens D; Diels J; van Sanden S; Pacou M
Curr Med Res Opin; 2020 Apr; 36(4):595-606. PubMed ID: 31960724
[No Abstract] [Full Text] [Related]
17. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.
Favale A; Onali S; Caprioli F; Pugliese D; Armuzzi A; Macaluso FS; Orlando A; Viola A; Fries W; Rispo A; Castiglione F; Mocci G; Chicco F; Usai P; Calabrese E; Biancone L; Monteleone G; Fantini MC;
Inflamm Bowel Dis; 2019 Oct; 25(11):1805-1812. PubMed ID: 30931477
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real-world data analysis.
Banon T; Weil C; Borsi A; Chodick G; Shakked Z; Barit Ben-David N
JGH Open; 2022 Feb; 6(2):120-125. PubMed ID: 35155821
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease.
Jung YS; Han M; Park S; Cheon JH
Gut Liver; 2021 Jan; 15(1):92-99. PubMed ID: 32839359
[TBL] [Abstract][Full Text] [Related]
20. Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn's Perianal Fistulae.
Maas L; Gao R; Cusumano V; Spartz E; Chowdhury R; Krishna M; Lazarev M; Melia J; Selaru F; Sharma S; Limketkai B; Parian A
Dig Dis Sci; 2023 Oct; 68(10):3994-4000. PubMed ID: 37540392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
